Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions
- PMID: 20731541
- DOI: 10.1515/BC.2010.089
Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions
Abstract
Alzheimer's disease (AD) is characterized by the extracellular deposition of the beta-amyloid protein (Abeta). Abeta is a fragment of a much larger precursor protein, the amyloid precursor protein (APP). Sequential proteolytic cleavage of APP by beta-secretase and gamma-secretase liberates Abeta from APP. The aspartyl protease BACE1 (beta-site APP-cleaving enzyme 1) catalyses the rate-limiting step in the production of Abeta, and as such it is considered to be a major target for drug development in Alzheimer's disease. However, the development of a BACE1 inhibitor therapy is problematic for two reasons. First, BACE1 has been found to have important physiological roles. Therefore, inhibition of the enzyme could have toxic consequences. Second, the active site of BACE1 is relatively large, and many of the bulky compounds that are needed to inhibit BACE1 activity are unlikely to cross the blood-brain barrier. This review focuses on the structure BACE1, current therapeutic strategies based on developing active-site inhibitors, and new approaches to therapy involving targeting the expression or post-translational regulation of BACE1.
Similar articles
-
P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.J Pharmacol Exp Ther. 2008 Aug;326(2):502-13. doi: 10.1124/jpet.108.138974. Epub 2008 May 22. J Pharmacol Exp Ther. 2008. PMID: 18499745
-
BACE1 in Alzheimer's disease.Clin Chim Acta. 2012 Dec 24;414:171-8. doi: 10.1016/j.cca.2012.08.013. Epub 2012 Aug 20. Clin Chim Acta. 2012. PMID: 22926063 Review.
-
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.J Neurochem. 2006 Dec;99(6):1555-63. doi: 10.1111/j.1471-4159.2006.04178.x. Epub 2006 Nov 2. J Neurochem. 2006. PMID: 17083447
-
Effects of peptides derived from BACE1 catalytic domain on APP processing.Peptides. 2007 Apr;28(4):838-44. doi: 10.1016/j.peptides.2007.01.006. Epub 2007 Jan 19. Peptides. 2007. PMID: 17293005
-
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.Biochem Soc Trans. 2007 Jun;35(Pt 3):574-6. doi: 10.1042/BST0350574. Biochem Soc Trans. 2007. PMID: 17511655 Review.
Cited by
-
Alzheimer's disease hypothesis and related therapies.Transl Neurodegener. 2018 Jan 30;7:2. doi: 10.1186/s40035-018-0107-y. eCollection 2018. Transl Neurodegener. 2018. PMID: 29423193 Free PMC article. Review.
-
Tripchlorolide Attenuates β-amyloid Generation via Suppressing PPARγ-Regulated BACE1 Activity in N2a/APP695 Cells.Mol Neurobiol. 2016 Nov;53(9):6397-6406. doi: 10.1007/s12035-015-9542-2. Epub 2015 Nov 19. Mol Neurobiol. 2016. PMID: 26582466
-
Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.Front Neurosci. 2022 Aug 4;16:939855. doi: 10.3389/fnins.2022.939855. eCollection 2022. Front Neurosci. 2022. PMID: 35992936 Free PMC article. Review.
-
Silencing of amyloid precursor protein expression using a new engineered delta ribozyme.Int J Alzheimers Dis. 2012;2012:947147. doi: 10.1155/2012/947147. Epub 2012 Feb 12. Int J Alzheimers Dis. 2012. PMID: 22482079 Free PMC article.
-
Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β-amyloid production and clearance.J Neurosci. 2013 Aug 7;33(32):13138-49. doi: 10.1523/JNEUROSCI.4790-12.2013. J Neurosci. 2013. PMID: 23926267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
